Rosenblatt analyst Blair Abernethy downgraded Synopsys (SNPS) to Neutral from Buy with a price target of $605, down from $650. The company’s fiscal Q3 results miss expectations largely due to a weaker intellectual property business, the analyst tells investors in a research note. The firm says management blamed the Q3 and outlook miss on several issues, including export restrictions in China, delays at a major foundry, and IP product decisions that did not yield as expected. Rosenblatt cut estimates through fiscal 2027, saying Synopsys IP business pivot will take several quarters to complete and creates increased uncertainty.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade SNPSPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNPS:
- Synopsys downgraded to Neutral from Buy at Rosenblatt
- Synopsys price target lowered to $550 from $650 at Stifel
- Synopsys price target lowered to $630 from $660 at Piper Sandler
- Synopsys double downgraded to Underperform at BofA on Intel, China overhangs
- Synopsys price target lowered to $550 from $630 at Wells Fargo